The Joint Venture Collaboration includes a portfolio of 13 life-changing brands across six therapeutic areas, with revenues primarily resulting from pain management medicines The collaboration is ...
- BridgeBio to receive upfront payment of USD 100 million with royalties up to the high-twenties percent, with additional milestone-based payments - Infigratinib is a once daily oral treatment option ...
Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine ...
Kyowa Kirin is expanding its scope to genetic medicines by acquiring Orchard Therapeutics, a company whose gene therapy for a rare inherited metabolic disorder is commercialized in Europe and is on ...
Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has ...
Kura Oncology and Kyowa Kirin announce FDA acceptance of ziftomenib NDA for relapsed/refractory AML, targeting a November 2025 decision. Kura Oncology and Kyowa Kirin announced that the FDA has ...
TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Following a biopharma industry trend, Kyowa Kirin is narrowing its focus by offloading some mature medicines. The Japanese drugmaker will spin its international established medicines portfolio into a ...
While the XLH Community Guidebook began as a joint effort between the XLH Network and Kyowa Kirin, future editions will be managed solely by the XLH Network following the site's transition at the end ...
Kyowa Kirin wants physicians to make the link between rare cancers that present on the skin to the blood connection underneath. Its new “Treat the Blood, Treat the Skin” campaign for Poteligeo, which ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results